Research programme: insulin sensitisers - Roche
Alternative Names: BM 131258Latest Information Update: 06 Aug 2003
Price :
$50 *
At a glance
- Originator Roche
- Class Small molecules; Thiazolidinediones
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 06 Aug 2003 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 06 Aug 2003 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 15 Jun 2000 Preclinical development for Obesity in USA (Unknown route)